Strategies for prophylaxis against prosthetic valve endocarditis: A review article

Journal of Heart Valve Disease

Volumn 7, Issue 3, 1998, Pages 316-326

  Hyde, Jonathan A J ^a,d   Darouiche, Rabih O ^b   Costerton, J William ^c  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MONTANA STATE UNIVERSITY   (United States)

^d NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ASEPSIS; BACTERIAL ENDOCARDITIS; BIOFILM; GRAFT INFECTION; HEART VALVE PROSTHESIS; HUMAN; INFECTION RISK; MORTALITY; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BIOFILMS; ENDOCARDITIS, BACTERIAL; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; INCIDENCE; PROSTHESIS-RELATED INFECTIONS; REOPERATION;

EID: 0031832010     PISSN: 09668519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Sandza JG, Clark RE, Ferguson TB, Connors JP, Weldon CS. Replacement of prosthetic heart valves. J Thorac Cardiovasc Surg 1977;74:864-868
2. Mayer KH, Schoenbaum SC. Evaluation and management of prosthetic valve endocarditis. Prog Cardiovasc Dis 1982;25(1):43-54
3. Ivert TSA, Dismukes WE, Cobbs CG, Blackstone EH, Kirklin JW, Bergdahl LAL. Prosthetic valve endocarditis. Circulation 1984;69:223-232
4. Tornos P, Sanz E, Permanyer-Miralda G, Almirante B, Planes AM, Soler-Soler J. Late prosthetic valve endocarditis. Immediate and long-term prognosis. Chest 1992;101(1):37-41
5. Kuyvenhoven JP, van Rijk-Zwikker GL, Hermans J, Thompson J, Huysmans HA. Prosthetic valve endocarditis: Analysis of risk factors for mortality. Eur J Cardiothorac Surg 1994;8:420-424
6. Vlessis AA, Khaki A, Grunkemeier GL, Li HH, Starr A. Risk, diagnosis and management of prosthetic valve endocarditis: A review. J Heart Valve Dis 1997;6:443-465
7. Starr A, Edwards ML. Mitral replacement: Clinical experience with a ball-valve prosthesis. Ann Surg 1961;154:726-740
8. Costerton JW, Lewandowski DE, Caldwell DE, Korber DR, Lappin-Scott HM. Microbial biofilms. Annu Rev Microbiol 1995;49:711-745
9. Costerton JW. Overview of microbial biofilms. J Indust Microbiol 1995;15:137-140
10. Costerton JW, Lappin-Scott HM. Introduction to microbial biofilms. In: Costerton JW, Lappin-Scott HM (ed). Microbial Biofilms. 1995:1-11
11. Davies DG, Geesey GG. Regulation of the alginate biosynthesis gene algC in Pseudomonas aeruginosa during biofilm development in continuous culture. Appl Environ Microbiol 1995;61(3):860-867
12. Stoodley P, de Beer D, Lewandowski Z. Liquid flow in biofilm systems. Appl Environ Microbiol 1994;60(8)
13. de Beer D, Stoodley P, Lewandowski Z. Liquid flow and mass transport in heterogeneous biofilms. Water Res 1996;30(11):2761-2765
14. Nickel JC, Wright JB, Ruseska I, Marrie TJ, Whitfield C, Costerton JW. Antibiotic resistance of Pseudomonas aeruginosa colonizing a urinary catheter in vitro. Eur J Clin Microbiol 1985;4(2):213-218
15. Nickel JC, Ruseska I, Wright JB, Costerton JW. Tobramycin resistance of Pseudomonas aeruginosa cells growing as a biofilm on urinary catheter material. Antimicrob Agents Chemother 1985;27(4):619-624
16. Sullam PM, Frank U, Yeaman MR, Tauber MG, Bayer AS, Chambers HF. Effect of thrombocytopenia on the early course of streptococcal endocarditis. J Infect Dis 1993;168(4):910-914
17. Ward KH, Olson ME, Lam K, Costerton JW. Mechanism of persistent infection associated with peritoneal implants. J Med Microbiol 1992;36(6):406-413
18. Characklis WG, Lee W, Peyton B, Lewandowski Z. Interactions between process waters, microbial biofilms and metal substrata. In: Dowling NJ, Mittelman MW, Danko JC (ed). Microbial Influenced Corrosion and Biodeterioration. University of Tennessee, Knoxville, 1990:59-63
19. Cogwill LD, Addonizio VP, Hopewau AR, Harken AH. Prosthetic valve endocarditis. Curr Probl Cardiol 1986;11:620
20. Sande MA, Johnson WD, Hook EW, Kaye D. Sustained bacteremia in patients with prosthetic valves. N Engl J Med 1972;286:1067-1070
21. Wilson WR, Danielson GK, Giuliani ER, Geraci JE. Prosthetic valve endocarditis. Mayo Clin Proc 1982;57:155-161
22. Rumisek JD, Albus RA, Clarke JS. Late Mycobacterium chelonei bioprosthetic valve endocarditis: Activation of contaminated implant? Ann Thorac Surg 1985;39:277-279
23. Lohr DC, Goeken JA, Doty DB, Donta S. Mycobacterium gordonae infection of a prosthetic valve. JAMA 1978;239:1528-1530
24. Weinstein L. Infective endocarditis. In: Braunwald E (ed). Heart Disease. WB Saunders, Philadelphia, 1988:1093-1129
25. Schoen FJ, Titus JL, Lawrie GM. Autopsy determined causes of death after cardiac valve replacement. JAMA 1983;249:899-902
26. Schoen FJ, Levy RJ. Bioprosthetic heart valve failure. Pathology and pathogenesis. Cardiol Clin 1984;2:717-239
27. Schoen FJ. Pathology of heart valve replacement. In: Steiner MD, Fernandez RM (ed). Guide to Prosthetic Cardiac Valves. Springer-Verlag, New York, 1985:209-247
28. Bailey IK, Richards JG. Infective endocarditis in a Sydney teaching hospital - 1962-1971. Aust NZJ Med 1975;5(5):413-420
29. Arnett EN, Roberts WC. Prosthetic valve endocarditis. Clinico-pathological analysis of 22 necroscopy patients with comparison of observations in 74 necroscopy patients with active infective endocarditis involving natural left-sided heart valves. Am J Cardiol 1976;38:281-292
30. Anderson DJ, Buckley BH, Hutchins GM. A clinicopathologic study of prosthetic valve endocarditis in 22 patients. Morphologic basis for diagnosis and therapy. Am Heart J 1977;94:325-332
31. Terada Y, Mitsui T, Yamamoto T. Bacterial colonies around the suture material in bacteraemia with a valve prosthesis (letter). Ann Thorac Surg 1994;58:911
32. Ferrans VJ, Boyce SW, Billingham ME, Spray TLR. Infection of glutaraldehyde preserved porcine valve heterografts. Am J Cardiol 1979;43:11231136
33. Clarkson PM, Barratt-Boyes BG. Bacterial endocarditis following homograft replacement of the aortic valve. Circulation 1970;42:987-991
34. Calderwood SB, Swinski LA, Waternaux CM, Karchmer AW, Buckley MJ. Risk factors for the development of prosthetic valve endocarditis. Circulation 1985;72(1):31-37
35. Rutledge R, Applebaum RE, Kim JB, Engler MB, Engler MM. Actuarial analysis of the risk of undergoing repeat cardiac valve replacement. Am J Surg 1984;148(3):357-361
36. Dorney ER, King SR. Bacterial endocarditis following prosthetic valve surgery. Early and late occurrence. Circulation 1970;41:150-161
37. Cowgill LD, Addonizio VP, Hopeman AR, Harken AH. Prosthetic valve endocarditis. Curr Probl Cardiol 1986;11(11):617-664
38. Karchmer AW. Prosthetic valve endocarditis: A continuing challenge for infection control. J Hosp Infect 1991;18(Suppl. A):355-366
39. Antunes MJ, Sanches MF, Fernandes LE. Antibiotic prophylaxis and prosthetic valve endocarditis. J Heart Valve Dis 1992;1(2):201-205
40. Slaughter L, Morris JE, Starr A. Prosthetic valvular endocarditis. A 12 year review. Circulation 1973;47:1318-1326
41. Dismukes WE, Karchmer AW, Buckley MJ, Austen WG, Swartz MN. Prosthetic valve endocarditis. Analysis of 38 cases. Circulation 1973;48(2):365-377
42. Wilson WR, Jaumin PM, Danielson GK. Prosthetic valve endocarditis. Ann Intern Med 1975;82:751-756
43. Block PC, DeSanctis RW, Weinberg AN, Austen WG. Prosthetic valve endocarditis. J Thorac Cardiovasc Surg 1970;60:540-548
44. Baumgartner WA, Miller C, Reitz BA, et al. Surgical treatment of prosthetic valve endocarditis. Ann Thorac Surg 1983;35(1):87-104
45. Barza M, Brusch J, Bergeron MG, Weinstein L. Penetration of antibiotics into fibrin loci in vivo. III. Intermittent versus continuous infusion and effect of probenecid. J Infect Dis 1974;129:73-78
46. Kay JH, Berstein S, Tsuji HK, Redington JV, Milgram M, Brem T. Surgical treatment of candida endocarditis. JAMA 1968;203(9):621-626
47. Wilson WE, Geraci JE. Antibiotic treatment of infective endocarditis. Annu Rev Med 1983;34:413-427
48. Masur H, Johnson D. Prosthetic valve endocarditis. J Thorac Cardiovasc Surg 1980;80:31-37
49. Karchmer AW, Dismukes WE, Buckley MJ, Austen WG. Late prosthetic valve endocarditis. Clinical features influencing therapy. Am J Med 1978;64:199-206
50. Rossiter SG, Stinson EB, Oyer PE, et al. Prosthetic valve endocarditis. Comparison of heterograft tissue valves and mechanical valves. J Thorac Cardiovasc Surg 1978;76:795-803
51. Saffle JR, Gardner P, Schoenbaum SC, Wild W. Prosthetic valve endocarditis. The case for prompt valve replacement. J Thorac Cardiovasc Surg 1977;73:416-420
52. Freeman R. Prevention of prosthetic valve endocarditis. J Hosp Infect 1995;30:44-53
53. Fang G, Keys TF, Gentry LO, et al. Prosthetic valve endocarditis resulting from nosocomial bacteremia. Ann Intern Med 1993;119:560-567
54. Wilson AP, Felmingham D, Gruneberg RN, Treasure T, Sturridge MF. Contamination of blood during cardiopulmonary bypass: The effect of antibiotic prophylaxis. J Hosp Infect 1988;12(1):35-42
55. Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial endocarditis. Recommendations by The American Heart Association. JAMA 1997;277:1794-1801
56. Brooks RG, Notario G, McCabe RE. Hospital survey of antimicrobial prophylaxis to prevent endocarditis in patients with prosthetic heart valves. Am J Med 1988;84(3):617-621
57. Actis Dato A, Chiusolo C, Cichitti GC, Actis Dato GM, Porro MC, Bello A. Pretrattamento antibiotico delle protesi valvolari. Minerva Cardioangiol 1992;40:225-229
58. Kinney EV, Bandyk DF, Seabrook GA, Kelly HM, Towne JB. Antibiotic-bonded PTFE vascular grafts: The effect of silver antibiotic on bioactivity following implantation. J Surg Res 1991;50:430-435
59. Jansen B, Rinck M, Wolbring P, Strohmeier A, Jahns T. In vitro evaluation of the antimicrobial efficacy and biocompatibility of a silver coated central venous catheter. J Biomater Appl 1994;9:55-70
60. Tweden KS, Cameron JD, Razzouk AJ, Holmberg WR, Kelly SJ. Biocompatibility of silver-modified polyester for antimicrobial protection of prosthetic valves. J Heart Valve Dis 1997;6:553-561
61. Tweden KS, Holmberg WR, Sioshansi P, et al. Silver coating of cardiovascular textiles for antimicrobial protection. 43rd Annual ASAIO Conference. Atlanta, GA, 1997
62. Bricault R, Tobin E, Karimy H, et al. Antimicrobial properties of silver based coatings for biomaterials. XIth World Congress of the International Society for Artificial Organs. Providence, RI, 1997
63. Bambauer R, Mestres P, Schiel R, Sioshansi P. New surface-treatment technologies for catheters used for extracorporeal detoxification methods. Dial Transpl 1995;24(5):228-237
64. Lau JKH, Robles A, Cherian MS, Ross DN. Surgical treatment of prosthetic endocarditis. J Thorac Cardiovasc Surg 1984;87:712-716
65. Ross DN. Homograft replacement of the aortic valve. Lancet 1962;2:487
66. Rose AG. Prosthetic valve endocarditis. A clinicopathological study of 31 cases. S Afr Med J 1986;69(7):441-445
67. Wahlig H, Dingeldein W, Bergmann R, Reuss K. Experimentelle und pharmakologische Untersuchungen mit Gentamicin-PMMA-Kugeln. Zentralbl Chir 1979;104:923-933
68. Olanoff LS, Anderson JM, Jones RD. Sustained release of gentamicin from prosthetic heart valves. Trans Am Soc Artif Intern Organs 1979;XXV:334-338
69. Karck M, Siclari F, Wahlig H, Sperling U, Schmid C, Haverich A. Pretreatment of prosthetic valve sewingring with the antibiotic/fibrin sealant compound as a prophylactic tool against prosthetic valve endocarditis. Eur J Cardiothorac Surg 1990;4(3):142-146
70. Powell TW, Burnham SJ, Johnson G. A passive system using rifampicin to create an infection-resistant vascular prosthesis. Surgery 1983;94:765-768
71. Avramovic JR, Fletcher JP. Rifampicin impregnation of a protein-sealed Dacron graft: An infection resistant prosthetic vascular graft. Aust NZJ Surg 1991;61:436-440
72. Colburn MD, Moore WS, Chvapil M, Gelabert HA, W.J. Q-B. Use of an antibiotic-bonded graft for in situ reconstruction after prosthetic graft infections. J Vasc Surg 1992;16:651-658
73. Torsello G, Sandmann W, Gehrt A, Jungblut RM. In situ replacement of infected vascular prostheses with rifampicin soaked vascular grafts: Early results. J Vasc Surg 1993;17:768-773
74. Chervu A, Moore WS, Chvapil M, Henderson T. Efficacy and duration of antistaphylococcal activity comparing three antibiotics bonded to Dacron vascular grafts with a collagen release system. J Vasc Surg 1991;13:897-901
75. Ashton TR, Cunningham D, Paton D, Maini R. Antibiotic loading of vascular grafts. Proc Soc Biomater 1990;13:235-241
76. Goeau-Brissoniere O, Mercier F, Nicholas MH. Treatment of vascular graft infection by in situ replacement with a rifampicin-bonded gelatin-sealed Dacron graft. J Vasc Surg 1994;19:739-741
77. French BG, Wilson K, Wong M, Smith S, O'Brien MF. Rifampicin antibiotic impregnation of the St. Jude Medical mechanical valve sewing-ring: A weapon against endocarditis. J Thorac Cardiovasc Surg 1995;112(2):248-252
78. Cimbollek M, Nies B, Wenz R, Kreuter J. Antibioticimpregnated heart valve sewing-rings for treatment and prophylaxis of bacterial endocarditis. Antimicrob Agents Chemother 1996;40(6):1432-1437
79. Garrison JR, Henke PK, Smith KR, et al. In vitro and in vivo effects of rifampicin on Staphylococcus epidermidis graft infections. Am Soc Artif Intern Organs J 1997;43:8-12
80. Raad I, Darouiche R, Dupuis J, et al. Central venous catheters coated with minocycline and rifampicin for the prevention of catheter related colonisation and bloodstream infections. Ann Intern Med 1997;127:267-274
81. Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of central venous catheter related bloodstream infection by use of an antiseptic-impregnated catheter. Ann Intern Med 1997;127:257-266
82. Khoury AE, Lam K, Ellis B, Costerton JW. Prevention and control of bacterial infections associated with medical devices. Am Soc Artif Intern Organs J 1992;38:174-178
83. Raad I, Darouiche R, Hachem R, Sacilowski M, Bodey GP. Antibiotics and prevention of microbial colonisation of catheters. Antimicrob Agents Chemother 1995;39(11):2397-2400
84. Darouiche RO, Dhir A, Miller AJ, Landon GC, Raad I, Musher DM. Vancomycin penetration into biofilm covering infected bioprostheses and effect on bacteria. J Infect Dis 1994;170(3):720-723
85. Davis CP, Wagle N, Anderson MD, Warren MW. Bacterial and fungal killing by iontopheresis with long-lived electrodes. Antimicrob Agents Chemother 1991;35:2131-2134
86. Davis CP, Weinberg S, Anderson MD, Rao GM, Warren MW. Effects of microamperage, medium and bacterial concentration on iontophoretic killing of bacteria in fluid. Antimicrob Agents Chemother 1989;33:442-447